Can Coffee Be the Secret Weapon Against Atrial Fibrillation?
Could your daily coffee habit be more than just a pick-me-up? A recent study, the DECAF trial, has sparked intrigue by revealing that a daily dose of caffeinated coffee might significantly reduce the risk of atrial fibrillation (AF) and flutter in patients with a history of sustained AF.
According to the research, patients who indulged in a cup of joe experienced a notable decrease in AF and flutter compared to those who abstained. This finding challenges the traditional advice given to arrhythmia patients, who are often cautioned to steer clear of caffeine.
But here's where it gets controversial: Dr. Gregory M. Marcus, a professor of medicine at the University of California, San Francisco, and coauthor of the study, suggests that AF patients need not refrain from caffeinated coffee. This statement is backed by the DECAF trial's results, which were presented at the American Heart Association (AHA) Scientific Sessions 2025 and published in JAMA.
Despite coffee being a staple beverage in the US, its health effects are surprisingly understudied. Previous observational data hinted that caffeinated coffee drinkers might have a lower risk of AF, but this randomized trial aimed to provide more concrete evidence.
Brewing the Perfect Remedy?
The DECAF trial was a prospective, open-label, randomized clinical trial involving 200 patients with AF or atrial flutter from the US, Canada, and Australia. These patients were all current or recent coffee drinkers, consuming an average of seven cups per week, and were scheduled for electrical cardioversion.
The primary focus was on the recurrence of AF or atrial flutter over a 6-month period. Patients were randomly divided into two groups: one continued their coffee habit, while the other abstained.
The results? The coffee-drinking group showed a significant advantage, with a 47% recurrence rate compared to 64% in the abstinence group. This benefit extended to AF recurrence alone, but not to flutter recurrence, which was relatively rare in the study population.
Importantly, no difference in adverse events was observed between the groups.
Dr. Andrea M. Russo, a professor of medicine at Cooper Medical School, highlighted that the DECAF trial's findings contradict the conventional advice to avoid caffeine for AF patients. However, she also cautioned that the study's results should not be generalized to other caffeinated beverages, as energy drinks were not part of the trial.
Brewing the Perfect Study?
While the DECAF trial offers intriguing insights, it's not without its limitations. Dr. Russo pointed out potential recall bias in self-reported caffeine intake and the varying strength of coffee cups. Additionally, the study did not measure other lifestyle factors known to influence AF, such as exercise, weight loss, and alcohol consumption.
Dr. Marcus acknowledged that the study's population was specific, including only those who had recently consumed caffeinated coffee regularly. This could mean that individuals with caffeine-induced AF who avoid coffee altogether were not represented.
Although the DECAF trial suggests a potential benefit of caffeinated coffee, this is where it gets controversial again: Dr. Marcus emphasized the need for further studies to confirm these findings before recommending coffee as an AF remedy. After all, the effects of caffeine on the heart are complex and not fully understood.
The study's authors disclosed financial interests and funding sources, ensuring transparency. Dr. Marcus reported receiving fees and equity from InCarda Therapeutics and research funding from various institutions, while Dr. Russo reported no relevant financial relationships.
So, should you swap your morning coffee for a decaf alternative? The jury is still out, but this study certainly adds an intriguing twist to the ongoing debate about coffee's health effects. What do you think? Is coffee a friend or foe when it comes to atrial fibrillation?
